Treatment
|
Patient Class
|
Time-to-Progression
|
Response
Rate
|
Reference | Dates
|
Prednimustine vs. CVP (COP)
|
246 pt - low grade with 10% high grade
|
31 vs. 14 mo.
|
|
Semin. Oncol., 1986;1 (suppl 1) 19-22 1986 abstract
|
CVP (COP) vs. Prednimustine/mixoxantrone
|
344/442 symptomatic follicular
|
14 vs. 31 mo.
|
|
Leukemia, 1996; 10: 836-43
|
CVP vs. Fludara
|
303/381 NHL Working formulation class ABC, CLL excluded
|
15 vs. 21 mo.
|
|
ASH 2001, Abstract 3501 Abstract
|
CHOP vs.
CHOP plus interferon
|
|
1.9 vs. 2.9 yrs
|
|
Blood, 1998; 92 (Suppl 1): 486
|
CHOP-B
B =
|
|
|
|
|
Alternating CHOP/FMD
|
87 NHLpts bulky
|
29 mo.
|
95% (79 CR in 83 evaluable pts.
|
Clin Lymphoma 2002 Mar;2(4):229-37 abstract
|
Other Studies presenting median Time to Progression
|
Vaccine responders vs. non-responders/ historical controls
|
follicular NHL
|
7.9 vs. 1.3 yrs (initial report)
>10 yrs vs. 1.3 yrs (last report)
|
|
J.Timmerman & R.Levy, Clinical Lymphoma 1(2), 129-139 (2000).
|
Vaccine vs. Antibody/Toxin (PACE Chemotherapy)
|
|
90% disease free at 3 yrs
vs. 50% at 2.2 yrs after PACE
|
|
1999
|
Not specified
|
Indolent, bcl2 positive
|
PCR-negative 73% 5 yr FFS
vs. PCR positive 28%
|
|
Ann Oncol 2000;11 Suppl 1:137-40
|
Fludarabine Mitoxantrone
|
8 Follicular
/11 CLL/SLL
|
15 mo
|
|
Hematol Oncol 1998 Sep;16(3):107-16
|
ProMacc+Mopp plus Radiation
|
Various
|
> 48 mo
|
|
Semin Hematol 1988 Apr;25(2 Suppl 2):11-6
|
FLU vs. FLU-ID(Idarubicine)
|
Mixed types
|
62% vs. 84% remained in remission at 19 mo.
|
|
J Clin Oncol 2000 Feb;18(4):773-9
1995-1998
|
Fludarabine/ Mitoxantrone/ Dexamethasone Alternating with CHOP
|
87
83 evaluable
follicular, bulky
|
29 mo.
|
95%
|
Clin Lymphoma 2002 Mar;2(4):229-37
|
Studies including Monoclonal Antibodies
|
CHOP plus Rituxan
Also see, PubMed: related articles
|
38
|
82.3 mo. Median duration (ASH 2003)
..." responses were durable with a progression-free survival and median duration of response >5 years." PMID: 12662126
|
100%, 63% - CR
|
J Clin Oncol 1999 Jan;17(1):268-76
ASH 2001, 2519
Drugs. 2003;63(8):803-43.
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
|
Fludara plus Rituxan
|
36
|
14+ mo. Median duration not reached
|
|
ASH 2001, 2518
|
Rituxan + interferon-alpha-2a
|
38
relapsed or refractory, lg follicular, NHL
|
25.2 mo. in responders
|
45% - 11% - CR, 34% - PR
|
Clin Cancer Res 2000 Jul;6(7):2644-52 abstract
|